Table 1 Randomized studies of WBRT and radiosensitizers versus WBRT alone
From: Whole brain radiotherapy with radiosensitizer for brain metastases
Study | Study arms | No. of pts randomized | Overall median survival | Overall survival at 6 months | Response (CR + PR) |
|---|---|---|---|---|---|
DeAngelis (19) | 3000 cGy/10 fr + lonidamine | 31 | 4.0 m | NR | 37% |
| Â | 3000 cGy/10 fr | 27 | 5.4 m | Â | 55% |
Eyre (20) | 3000 cGy/10 fr + metronidazole | 57 | 2.8 m | 14 | 27% |
| Â | 3000 cGy/10 fr | 54 | 3.2 m | 13 | 24% |
RTOG-7916(21) | 3000 cGy/6 fr + misonidazole | 220 | 3.1 m | 68 | NR |
| Â | 3000 cGy/6 fr | 216 | 4.1 m | 83 | Â |
| Â | 3000 cGy/10 fr + misonidazole | 211 | 3.9 m | 65 | Â |
| Â | 3000 cGy/10 fr | 212 | 4.5 m | 72 | Â |
Mehta(23) | 3000 cGy/10 fr + MGd | 193 | 5.2 m | 82 | NR |
| Â | 3000 cGy/10 fr | 208 | 4.9 m | 85 | Â |
RTOG-8905(22) | 3750 cGy/15 fr + BrdUrd | 35 | 4.3 m | 12 | 63% |
| Â | 3750 cGy/15 fr | 37 | 6.12 m | 20 | 50% |
REACH (25) | 3000 cGy/10 fr + RSR13 | 265 | 5.4 m | 119 | 48% |
| Â | 3000 cGy/10 fr | 250 | 4.4 m | 96 | 36% |
RTOG- 0118(26) | 3750cGy/15 fr + thalidomide | 90 | Â | Â | NR |
| Â | 3750 cGy/15 fr | 93 | Â | Â | Â |
SMART(24) | 3000 cGy/10 fr + MGd | 279 | NR | NR | NR |
| Â | 3000 cGy/10 fr | 275 | Â | Â | Â |